Quantum Biopharma (NASDAQ:QNTM) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Quantum Biopharma (NASDAQ:QNTM) from a strong sell rating to a sell rating in a research note published on Saturday morning.

Separately, Weiss Ratings cut shares of Quantum Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 28th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Quantum Biopharma Stock Up 5.5%

Shares of NASDAQ:QNTM opened at $3.05 on Friday. Quantum Biopharma has a fifty-two week low of $2.07 and a fifty-two week high of $31.91. The stock has a market cap of $19.52 million, a price-to-earnings ratio of -0.37 and a beta of 0.43. The firm’s 50 day moving average price is $3.88 and its 200 day moving average price is $4.25.

Hedge Funds Weigh In On Quantum Biopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in QNTM. Jane Street Group LLC purchased a new position in Quantum Biopharma in the fourth quarter valued at approximately $80,000. Virtu Financial LLC acquired a new stake in Quantum Biopharma during the 4th quarter worth $76,000. Finally, Platform Technology Partners purchased a new stake in Quantum Biopharma in the first quarter valued at $199,000. 1.24% of the stock is owned by institutional investors and hedge funds.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.